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Progression-free survivala b s t r a c t
Our previous study found that runt-related transcription factor-2 (RUNX2) was upregulated in
human epithelial ovarian cancer (EOC) tissues and may be involved in tumor progression and prog-
nosis. The aim of this study was to investigate the mechanism by which RUNX2 is aberrantly
expressed in EOC. We ﬁrstly conﬁrmed that miRNA-23b directly targets RUNX2 in EOC. Then, ectopic
expression of miR-23b signiﬁcantly inhibited ovarian cancer cell proliferation and tumorigenicity
by regulating the expression of RUNX2. Furthermore, the down-regulation of miR-23b was signiﬁ-
cantly correlated with tumor aggressiveness and poor prognosis of patients with EOC. Collectively,
miR-23b may function as tumor suppressor through inhibiting the upregulation of RUNX2, and may
be a potential prognostic marker for EOC.
 2014 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Human ovarian cancer, one of the most common gynecologic
malignancies worldwide, has the highest mortality rate among
malignant tumors in female reproductive system [1]. The morpho-
logical origin of ovarian cancer is complicated, including cancers of
epithelial, germ cell, undifferentiated and differentiated mesen-
chymal origin [2]. Among them, epithelial ovarian cancer (EOC) is
the ﬁfth leading cause of cancer death in women and the most
lethal gynecologic malignancy in the world [3]. It includes serous
adenocarcinoma, clear cell carcinoma and endometrial adenocarci-
noma [4]. Because of the lack of speciﬁc early symptoms or effec-
tive tumor biomarkers, most patients with EOCs are diagnosed at
the advanced stages and the prognosis of these patients is still
poor, even though there has been great improvement on tradi-
tional treatments, such as surgery, supplemented with radiother-
apy and chemotherapy. The 5-year survival rate for EOC patients
is only 30–40% [5]. It has been demonstrated that EOC may be
associated with multistep changes in various molecules. Althougha large number of studies have shown a great potential for the use
of molecular markers in diagnosis, prognosis, and therapy in EOC,
their clinical values are limited due to lack of sensitivity, high costs
and or inconvenience. Therefore, it is extremely necessary to iden-
tify novel and efﬁcient biomarkers used in the diagnosis and as
therapeutic targets for human EOC.
MicroRNAs (miRNAs), originally identiﬁed in Caenorhabditis
elegans, are a class of single-stranded, small (17–25 nt), non-coding,
evolutionarily conserved RNAs [6]. They regulate gene expression
by binding to imperfect complementary sites in the 30-untranslated
region of their target messenger RNA transcripts, and exert
their negative regulation either by degrading the target mRNA,
when they bind with near-perfect complementarity, or by post-
transcriptionally repressing target-gene expression when they
bind with imperfect complementarity [7]. In recent years, increas-
ing amounts of experimental evidence have suggested that
miRNAs may play important roles in essential processes, such as
differentiation, cell growth, stress response and cell death, and
may be involved in several human diseases, including cancer [8].
They function as either tumor suppressors or oncogenes by
repressing the expression of important cancer-related genes.
Especially in human EOC, accumulating studies have found the
aberrant expression of miRNAs which were associated with tumor
Table 1
Association of microRNA-23b (miR-23b) expression with clinicopathological features
of epithelial ovarian cancer tissues.





<50 48 26 (54.17) 22 (45.83) NS
P50 68 34 (50.00) 34 (50.00)
Clinical stage
I–II 26 4 (15.38) 22 (84.62) 0.02
III–IV 90 56 (62.22) 34 (37.78)
Pathological grade
1–2 33 17 (51.52) 16 (48.48) NS
3 83 43 (51.81) 40 (48.19)
Histological type
Serous 88 45 (51.14) 43 (48.86) NS
Non-serous 28 15 (53.57) 13 (46.43)
Residual tumor after surgery 60 56
<1 cm 66 35 (53.03) 31 (46.97) NS
P1 cm 50 25 (50.00) 25 (50.00)
Note: ‘NS’ refers to the difference without statistical signiﬁcance.
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ple, Wu et al. [9] reported that miR-145 may modulate ovarian
cancer growth and invasion by suppressing p70S6K1 and MUC1,
functioning as a tumor suppressor; Wang et al. [10] indicated that
miR-182 may promote cell growth, invasion, and chemoresistance
by targeting PDCD4 in human EOC; Zhang et al. [11] showed that
mR-124 may inhibit the migration and invasion of ovarian cancer
cells by targeting SphK1. These ﬁndings suggest that miRNAs
may be involved in ovarian tumorigenesis and cancer progression.
Mammalian Runt-related transcription factor (RUNX) family
contains three members (RUNX1–3) which form the core binding
factor (CBF) complex and bind DNA to either activate or repress
gene transcription [12]. Accumulating studies have reported the
oncogenic and tumor suppressive functions of the RUNX members
[13]. In the previous study, our data suggest for the ﬁrst time that
RUNX2 overexpression may be associated with advanced tumor
progression and poor clinical outcome of EOC patients, and RUNX2
might be a novel prognostic marker of EOC [14]. More recently,
Wang et al. [15] further demonstrated that the inhibition of RUNX2
transcriptional activity may block the proliferation, migration and
invasion of EOC cells, suggesting that RUNX2 might be a novel EOC
therapeutic target. However, the mechanisms by which RUNX2 is
aberrantly expressed in EOC have not been fully elucidated. Thus,
we in the current study used miRNA target prediction program
TargetScan6.2 to predict miR-23b as a candidate miRNA that tar-
gets RUNX2. Then, the regulatory function of miR-23b to RUNX2
was validated by transient transfection of the EOC cells in vitro
with oligonucleotides that mimic miR-23b and the luciferase
reporter assay. Moreover, the roles of miR-23b in tumorigenicity
of EOC cells were also investigated in vitro system. Furthermore,
we determined the clinical relevance of miR-23b in EOC.
2. Materials and methods
2.1. Patients and tissue samples
The study was approved by the Research Ethics Committee of
General Hospital of PLA, China. Informed consent was obtained
from all of the patients. All specimens were handled and made
anonymous according to the ethical and legal standards.
A total of 116 EOC specimens and 5 normal ovarian tissues were
snap-frozen in liquid nitrogen and stored at 80 C following sur-
gery for qRT-PCR and in situ hybridization assays. The normal ovar-
ian tissues were obtained from women who underwent
hysterectomies for benign disease. All operations were performed
in the Department of Obstetrics and Gynecology at General Hospi-
tal of PLA from January 2005 to December 2006. All patients with
only gynecology tumor were treated without preoperative radio-
therapy, chemotherapy, or hormonal therapy. Surgical staging
was established according to the International Federation of Gyne-
cology and Obstetrics (FIGO) system. Debulking status was deﬁned
according to the size of the nodules left in the peritoneal cavity
after surgery. The clinical features of 116 EOC patients were sum-
marized in Table 1.
2.2. Cell culture
Two EOC cell lines SKOV3 and OVCAR3 were purchased
from American Tissue Type Collection (Manassas, VA) and were
maintained at 37 C in a humidiﬁed chamber supplemented with
5% CO2.
2.3. Target prediction
An online program Target-Scan (release 6.2) was used for
predicting miRNAs that might target RUNX2.2.4. RNA and miRNA extraction
For mRNA quantiﬁcation, total RNAs from cell lines and tissues
were extracted using Trizol reagent (Invitrogen) according to the
manufacturer’s instructions. For miRNA quantiﬁcation, total miR-
NA was extracted from cell lines and tissues using the mirVana
miRNA Isolation Kit (Ambion, Austin, TX, USA) according to the
manufacturer’s instructions.
2.5. QRT-PCR
For mRNA and miRNA quantiﬁcations, stem-loop RT-PCR was
performed to respectively detect the expression levels of miR-
23b and RUNX2 in cell lines and tissues. In brief, 10 lg of small
RNA and 20 lg of total RNA were reverse transcribed into cDNA
using M-MLV reverse transcriptase (Promega, Madison, WI) with
the RT primers which can fold into a stem-loop structure. The
cDNA was used for the ampliﬁcation of mature miR-23b, RUNX2
and the endogenous controls, U6 and b-actin, by PCR. The PCR con-
ditions were: initial denaturation at 95 C for 5 min, followed by 40
cycles of 95 C for 30 s, 56 C for 30 s, and 72 C for 30 s.
Real-time PCR was performed using SYBR Green PCR Master
Mix (Applied Biosystems) on an ABI 7300HT real-time PCR system
(Applied Biosystems, Foster City, CA, USA). Gene and miRNA
expression in each sample were respectively normalized with the
housekeeping genes (b-actin and RNU6B) expression. Relative
quantiﬁcation of target gene expression was evaluated using the
2DDCT method.
2.6. EGFP-miR-23b expression vector
As the previous study [16], we got the commercial pGCMV/
EGFP/Neo-Vector(GenePharma, China) with an over-expression of
miR-23b, and the same negative-vector as control. EOC cells were
transfected through Fugene transfecting agents (Roche) with
hsa-miR-23b vector, negative control (NC) following the manufac-
turer’s instructions.
2.7. Western blot analysis
Proteins in EOC cells were extracted at 24 h post-transfection
and Western blot analysis was performed to detect the expression
1610 W. Li et al. / FEBS Letters 588 (2014) 1608–1615levels of RUNX2 protein. Proteins (40 lg) were fractioned by
SDS–PAGE and transferred onto Hybond nitrocellulose membranes
(GE Healthcare). Filters were blocked in PBS-Tween skim milk
and probed with anti-RUNX2 antibody (dilution 1:1000, AbnovaFig. 1. MicroRNA-23b (miR-23b) targets runt-related transcription factor-2 (RUNX2) in e
MiR-23b is downregulated in human EOC tissues detected by qRT-PCR analysis; (C) Repre
magniﬁcation 400). Red arrows point out the cells with positive expression of miR-23b.
transfection of miR-23b vector. b-Actin was used as an internal loading control. ‘NC’ ref
conﬁrm the miR-23b binding target. The luciferase activity was detected after co-trans
vector), miR-23b mimic or negative mimic into SKOV3 and OVCAR3 cells.Corporation, Taipei, Taiwan) or probed with anti-b-actin antibody
(Santa Cruz Biotechnology, Santa Cruz, USA). b-Actin was used as
equal protein loading control. The secondary antibody incubations
were performed for 2 h at room temperature and protein bandspithelial ovarian cancer (EOC) tissues. (A) MiR-23b is predicted to target RUNX2; (B)
sentative examples of miR-23b expression veriﬁed by in situ hybridization (Original
(D–F) The RUNX2 protein in SKOV3 and OVCAR3 cells by Western blot at 24 h post-
ers to negative control vector. (G and H) Luciferase report assay was performed to
fection of FLuci vector (30-UTR-RUNX2wt FLuci vector or 30-UTR-RUNX2mut FLuci
W. Li et al. / FEBS Letters 588 (2014) 1608–1615 1611were visualized by SuperSignal West PICO chemiluminescent
detection system (Pierce Biotechnology).
2.8. 30-UTR luciferase reporter assay
The miR-23b-targeted gene was evaluated by using a luciferase
reporter assay in EOC cells. The FLuci (30-UTR of RUNX2 luciferase)
vector was constructed using the pGL3 luciferase reporter vector
(Promega, Madison, WI, USA) with a fragment of mRNA 30-UTR of
RUNX2, which carries a putative miR-23b complementary site
(NM_006793.2; 30-UTR: 460-529) or mutation sequence. EOC cells
were cultivated in 24-well plates and were co-transfected using
Fugene (Roche) with 100 ng of FLuci reporter construct, 10 ng
miR-23b mimic or NC mimic, and 2 ng pRL-SV40 RLuci vector
(Promega). After 48 h, EOC cells were harvested and luciferase
activity was measured using the Dual- Luciferase Reporter Assay
System (Promega). The Renilla luciferase activities were used as
an internal control. The experiments were performed indepen-
dently in triplicate.
2.9. Small interfering RNA (siRNA)-mediated RUNX2 knockdown in
EOC cells
EOC cells were grown in complete 1640 medium in 10 ml cell
culture plates until 50% conﬂuence, and then transfected using
LipofectamineTM 2000 transfection reagent (Invitrogen) according
to the manufacturer’s instructions. The siRNA against RUNX2 and
the control siRNA were synthesized by QIAGEN China Co.,
Shanghai, China. For every 105 cells, 0.5 lg RUNX2 siRNA (RUNX2
target sequence AATGGCAGCACGCTATTAAAT) or control siRNA
(target sequence AATTCTCCGAACGTGTCACGT) was diluted and
mixed with 3 ll transfection reagent. After mixing and incubation
for 30 min, the transfection mixture was added to the cells. After
6 h, medium was changed to growth medium. EOC cells were used
for functional assay 24 h after transfection.
2.10. In vitro invasion and migration assays
Cell invasion and migration were respectively analyzed by
Matrigel coated and uncoated transwell cell culture chambers
(8 lm pore size, Millipore, Billerica, MA, USA) as described previ-
ously [17]. In brief, 48 h after transfection, EOC cells were resus-
pended in 200 ll serum-free 1640 medium were placed into the
upper chamber of the insert with or without Matrigel. Medium
with 5% FBS was added into the lower chambers as a chemoattrac-
tant. After 24 h of incubation, cells remaining on the upper mem-
brane were carefully removed. Cells that had migrated or
invaded through the membrane were manually counted at 200
magniﬁcation from ten different ﬁelds of each ﬁlter. All experi-
ments were done in triplicate. Mean normalized gene expres-
sion ± S.E. was calculated from independent experiments.
2.11. In vitro cell proliferation assay
The in vitro cell proliferation of EOC cells was measured using
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) method following the protocol of the previous studies [17].
In brief, cells were seeded into 96-well plates and transfected. At
48 h after transfection, 20 ll MTT solution (Sigma, USA) was added
into the culture medium for 4 h incubation. Then, the medium was
replaced by 0.1 ml of DMSO (Sigma, St Louis, MO, USA) and plates
were shaken at room temperature for 10 min. The absorbance at
490 nm was measured using a mQuant Universal Microplate
Spectrophotometer (BioTek, Winooski, VT). All experiments were
done in triplicate. Mean normalized gene expression ± S.E. was cal-
culated from independent experiments.2.12. In situ hybridization
Expression patterns and subcellular localizations of miR-23b in
EOC and normal ovarian tissues were detected by in situ hybridiza-
tion. The 50 end biotinylated Locked nucleic acid-modiﬁed probes
(Exiqon, Denmark), which is directed against full-length mature
miR-23b sequence, were used for this experiment on frozen sec-
tion of tissues. Following the incubation of substrate-chromogen
solution with 0.04% DAB (DAKO, Denmark) and 0.05% H2O2 for
30 min, the tissue sections were detected using the in situ hybrid-
ization kit (Cat No: MK1030, Boster, China) according to manufac-
turer’s instructions.
The in situ hybridization results were scored by two indepen-
dent experienced pathologists, who were blinded to the clinico-
pathological parameters of the patients. The scores of the two
pathologists were compared and any discrepant scores were
trained through re-examining the stainings by both pathologists
to achieve a consensus score. The in situ hybridization scores were
calculated based on both the intensity of hybridization and the
percentage of positive cells. The former was visually scored and
stratiﬁed as follows: 0 (negative), 1 (weak), 2 (moderate) and 3
(strong). The latter was as follows: 0 (0%), 1 (1–10%), 2 (11–50%)
and 3 (>50%). A ﬁnal score was obtained for each case by multiply-
ing the intensity and the percentage scores.
2.13. Statistical analysis
The software of SPSS version13.0 for Windows (SPSS Inc, IL,
USA) and SAS 9.1 (SAS Institute, Cary, NC) was used for statistical
analysis. Continuous variables in Figs. 1B, E, F, 2B, 3 and 4 were
expressed as X  s. Categorical variables in Table 1 are presented
as numbers and percentages. Comparisons between groups were
performed using the Kruskal–Wallis test for continuous variables
and the v2 test for categorical variables. The Kaplan–Meier method
was used for survival analysis, and differences in survival were
estimated using the log-rank test. A multivariate survival analysis
was performed for all parameters that were signiﬁcant in the
univariate analyses using the Cox regression model. Differences
were considered statistically signiﬁcant when Pwas less than 0.05.
3. Results
3.1. MiRNA-23b targets RUNX2 in EOC tissues
In the previous study, we performed the immunohistochemis-
try analysis and found that the expression level of RUNX2 protein
in EOC tissues was signiﬁcantly higher than that in normal ovarian
tissues (P < 0.001) and its overexpression was associated with ad-
vanced tumor progression and poor clinical outcome of patients
with EOC [14]. In the current study, using miRNA target predicting
program (TargetScan human 6.2), three miRNAs miR-23a, miR-23b
and miR-23c were all predicted to target RUNX2 (Fig. 1A).
According to our literature retrieval, there were no previous stud-
ies on the involvement of miR-23a and miR-23c in EOC. In contrast,
Park et al. [18] indicated that the aberrant expression of miR-23b
might be signiﬁcantly implicated in chemoresistance and tumor
progression in ovarian cancer. On this basis, we chose miR-23b
as a candidate miRNA which targets RUNX2 during the
tumorigenicity of EOC. To test our hypothesis, qRT-PCR, in situ
hybridization, transient transfection of the two EOC cell lines with
miR-23b vector plasmid, and luciferase reporter assay were
performed.
According to the results of qRT-PCR analysis, miR-23b expres-
sion in EOC tissues was signiﬁcantly lower than that in normal
ovarian tissues (3.83 ± 1.49 vs. 6.73 ± 1.22, P < 0.001, Fig. 1B). We
also validated the miR-23b expression by in situ hybridization.
Fig. 2. Down-regulation of runt-related transcription factor-2 (RUNX2) by siRNA interference. (AD) Western blot analysis was performed to detect the expression levels of
RUNX2 protein in RUNX2 siRNA-transfected (SKOV3-S and OVCAR3-S), control siRNA-transfected (SKOV3-C and OVCAR3-C) and non-transfected (SKOV3 and OVCAR3) cells.
b-Actin was used as an internal loading control.
Fig. 3. MicroRNA-23b (miR-23b) inhibits cell proliferation of epithelial ovarian cancer (EOC) cells in vitro by targeting runt-related transcription factor-2 (RUNX2). (A and C)
Growth curves of SKOV3 and OVCAR3 cells transfected with control siRNA (SKOV3-C and OVCAR3-C), and SKOV3 and OVCAR3 cells transfected with control siRNA and miR-
23b (SKOV3-C-miR-23b and OVCAR3-C-miR-23b). (B and D) Growth curves of SKOV3 and OVCAR3 cells transfected with RUNX2 siRNA (SKOV3-S and OVCAR3-S), and SKOV3
and OVCAR3 cells transfected with RUNX2 siRNA and miR-23b (SKOV3-S-miR-23b and OVCAR3-S-miR-23b).
1612 W. Li et al. / FEBS Letters 588 (2014) 1608–1615As shown in Fig. 1C, miR-23b was localized in the cytoplasm
of tumor cells in EOC tissues, and its expression levels in EOC
tissues were signiﬁcantly lower than those in normal ovarian
tissues (staining score: EOC = 3.62 ± 1.31 vs. Normal = 5.58 ± 1.69,P < 0.001), which was consistent with the results of qRT-PCR
analysis.
In order to verify our predicted target of hsa-miR-23b, we trans-
fected EOC cells with hsa-miR-23b vector, negative vector (NC),
Fig. 4. MicroRNA-23b (miR-23b) inhibits epithelial ovarian cancer (EOC) cells migration and invasion in vitro by targeting runt-related transcription factor-2 (RUNX2). (A and
C) Transwell migration assay and Matrigel invasion assay of EOC cells transfected with control siRNA (SKOV3-C and OVCAR3-C), and EOC cells transfected with control siRNA
and miR-23b (SKOV3-C-miR-23b and OVCAR3-C-miR-23b). (B and D) Transwell migration assay and Matrigel invasion assay of EOC cells transfected with RUNX2 siRNA
(SKOV3-S and OVCAR3-S), and EOC cells transfected with RUNX2 siRNA and miR-23b (SKOV3-S-miR-23b and OVCAR3-S-miR-23b). Enforced expression of miR-23b
signiﬁcantly inhibited the cell migration and invasion of EOC cells transfected with control siRNA (SKOV3-C-miR-23b vs. SKOV3-C and OVCAR3-C-miR-23b vs. OVCAR3-C) but
failed to do so in EOC cells transfected with RUNX2 siRNA (SKOV3-S-miR-23b vs. SKOV3-S and OVCAR3-S-miR-23b vs. OVCAR3-S).
W. Li et al. / FEBS Letters 588 (2014) 1608–1615 1613and blank control culture medium (mock), respectively. At 24 h
post-transfection, Western blot analysis showed that the enforced
expression of hsa-miR-23b resulted in a signiﬁcant decrease of
endogenous RUNX2 protein levels compared with cells trans-
formed with NC or mock (SKOV3 and OVCAR3 cell groups: both
P = 0.001, Fig. 1D–F). Moreover, the luciferase reporter assay was
performed by co-transfection of miR-23b and a luciferase reporter
plasmid containing the 30UTR of human RUNX2. Luciferase activity
was detected at 48 h after the co-transfection of FLuci vector
(30-UTR-RUNX2wt FLuci vector or 30-UTR-RUNX2mut FLuci vector),
miR-23b mimic or NC mimic, and RLuci vector in SKOV3 and
OVCAR3 cells. As shown in Fig. 1G and H, the luciferase activities
were respectively decreased to 0.63 and 0.68 in SKOV3 and
OVCAR3 cells co-transfected with 30-UTR-RUNX2wt FLuci vector
and miR-23b mimic compared with 30-UTR-RUNX2mut FLuci
vector and NC mimic.
Based on the evidence mentioned above, we conﬁrmed that
miR-23b may directly target RUNX2.
3.2. MiR-23b inhibits cell proliferation of EOC cells in vitro by targeting
RUNX2
To verify whether miR-23b inhibited cell proliferation of EOC
cell lines SKOV3 and OVCAR3 by targeting RUNX2, we ﬁrstly
knocked down the expression of RUNX2 by siRNA transfection.
As shown in Fig. 2, the expression level of RUNX2 protein in SKOV3
and OVCAR3 cells transfected with RUNX2 siRNA was signiﬁcantly
lower than that in SKOV3 and OVCAR3 cells transfected with or
without control siRNA (both P < 0.001). In addition, we found that
the enforced expression of miR-23b signiﬁcantly inhibited cell pro-
liferation of SKOV3 and OVCAR3 cells transfected with control siR-
NA (both P = 0.01, Fig. 3A and C) but failed to do so in SKOV3 andOVCAR3 cells transfected with RUNX2 siRNA (both P > 0.05, Fig. 3B
and D). Thus, miR-23b may inhibit the cell proliferation of EOC cell
lines by targeting RUNX2.
3.3. MiR-23b inhibits EOC cells migration and invasion in vitro by
targeting RUNX2
To verify whether miR-23b inhibited the cell migration and
invasion of the two EOC cell lines by targeting RUNX2, we made
use of SKOV3 and OVCAR3 cells in which RUNX2 was knocked
down by RUNX2 siRNA transfection. As shown in Fig. 4, the
enforced expression of miR-23b signiﬁcantly inhibited the cell
migration and invasion of SKOV3 and OVCAR3 cells transfected
with control siRNA (both P = 0.001, Fig. 4A and C) but failed to do
so in SKOV3 and OVCAR3 cells transfected with RUNX2 siRNA
(both P > 0.05, Fig. 4B and D). Therefore, miR-23b may suppress
EOC cell metastasis via negatively regulating the migratory and
invasive abilities of EOC cells by targeting RUNX2.
3.4. Association of miRNA-23b expression with the clinicopathological
characteristics of EOC
Table 1 summarized the association of miRNA-23b expression
with various clinicopathological features of EOC tissues. The med-
ian value (3.75) of miR-23b expression in all EOC tissues detected
by qRT-PCR were used as a cutoff point to classiﬁed 116 patients
with EOC into miR-23b-low (n = 60) and miR-23b-high (n = 56)
expression groups. As the results, the EOC tissues with advanced
clinical stage (III–IV) more frequently showed lowmiR-23b expres-
sion than those with low clinical stage (I–II, P = 0.02, Table 1).
However, miR-23b expression was not correlated with age, grade,
histological type and residual tumor after surgery (all P > 0.05).
Fig. 5. Kaplan–Meier overall (A) and progression-free (B) survival curves for epithelial ovarian cancer patients with high and low miR-23b expression. Epithelial ovarian
cancer patients with low miR-23b expression had signiﬁcantly shorter overall (P < 0.001) and progression-free (P < 0.001) survival than those with high miR-23b expression
did.
Table 2
Univariate analysis: factors predicting overall and progression-free survival.
Characteristic Groups Overall survival Progression-free survival
P value Hazard ratio (95% CI) P value Hazard ratio (95% CI)
Age (years) <50 vs. P50 0.16 1.582 (0.832–3.168) 0.27 1.001 (0.739–2.802)
Clinical stage I–II vs. III–IV <0.001 10.859 (1.942–26.919) 0.008 7.736 (1.219–19.573)
Pathological grade 1–2 vs. 3 0.06 4.266 (1.031–10.533) 0.09 3.152 (1.006–8.131)
Histological type Serous vs. non-serous 0.05 6.852 (1.062–11.781) 0.08 4.026 (1.022–9.781)
Residual tumor after surgery <1 cm vs. P1 cm 0.11 3.049 (1.001–7.103) 0.25 2.892 (0.903–6.098)
miR-23b expression Low vs. High <0.001 16.869 (1.859–39.262) <0.001 17.188 (1.876–40.986)
Table 3
Multivariate analysis: factors predicting overall and progression-free survival.
Characteristic Overall survival Progression-free survival
P value Hazard ratio (95% CI) P value Hazard ratio (95% CI)
Clinical stage 0.01 8.236 (1.182–20.601) 0.03 6.968 (1.012–15.872)
miR-23b expression 0.01 8.889 (1.368–21.328) 0.01 8.121 (1.332–20.269)
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In order to investigate the prognostic implications of miR-23b
expression in overall survival and progression-free survival of
EOC, the detail clinical information of all 116 EOC patients in high
miR-23b expression and low miR-23b expression groups was
reviewed. Median follow-up time was 66.8 months (range,
2.2–118.9 months; mean, 66.1 months). At last follow-up, 73
(62.9%) relapsed with a median time of 22.1 months (range,
2.8–85.2 months). As determined by the log-rank test, EOC
patients with low miR-23b expression had signiﬁcantly shorter
overall (P < 0.001, Fig. 5A) and progression-free (P < 0.001,
Fig. 5B) survival than those with high miR-23b expression did.
Moreover, the univariate analysis revealed that both the advanced
stage (P < 0.001 and P = 0.008, respectively) and low miR-23b
expression (both P < 0.001) predicted poorer overall and progres-
sion-free survival of EOC patients (Table 2). Furthermore, the mul-
tivariate analyses identiﬁed clinical stage (P = 0.01 and P = 0.03,
respectively) and miR-23b expression (both P = 0.01) in EOC cells
as independent prognostic factors for overall survival and progres-
sion-free survival (Table 3).
4. Discussion
Despite great efforts in clinical and basic research, the high
mortality of human EOC is due to late-stage diagnosis for more
than 70% of cases, and is also due to the common resistance to
the current chemotherapeutic regimens [19,20]. Elucidating themechanisms underlying tumorigenesis and tumor progression will,
thus, make signiﬁcant contributions toward combating this dis-
ease. In recent years, miRNAs have been demonstrated to be
important players in human cancer and their roles as therapeutic
targets have been proposed. Accumulating studies have identiﬁed
a number of miRNAs which are remarkably deregulated in EOC,
suggesting that miRNAs are involved in the initiation and progres-
sion of this disease [9–11]. In the current study, the main ﬁndings
are as following four points. Firstly, the miRNA target prediction
program TargetScan was used to predict a miRNA–miR-23b as a
candidate regulator for RUNX2 expression. Using the two EOC cell
lines SKOV3 and OVCAR3 transfected with miR-23b overexpres-
sion vector, we validated that RUNX2 was down-regulated at pro-
tein level by the proposed target miRNA, miR-23b, which was also
conﬁrmed by the luciferase reporter assay, suggesting that miRNA-
23b directly targets RUNX2 in EOC tissues. Secondly, the enforced
expression of miR-23b inhibited the cell proliferation and tumori-
genicity of the two EOC cell lines SKOV3 and OVCAR3 in vitro by
targeting RUNX2. Thirdly, both qRT-PCR and in situ hybridization
assays found that the expression level of miR-23b was decreased
in clinical EOC tissues. Finally, the down-regulation of miR-23b
in clinical EOC tissues was associated with the advanced tumor
progression and poor prognosis of patients with this disease. These
ﬁndings suggest that miR-23b may function as a tumor suppressor
in EOC by targeting RUNX2.
MiR-23b, which is located in one genomic cluster (miR-23b/
27b/24), has been demonstrated to be deregulated in several types
of cancer, including prostate cancer, bladder cancer, colon cancer,
W. Li et al. / FEBS Letters 588 (2014) 1608–1615 1615renal cancer, breast cancer and hepatocellular carcinoma [21–25].
Functionally, it acts as tumor promoter or tumor suppressor
depending on speciﬁc cancer types. For example, miR-23b is highly
upregulated in human breast cancer and its overexpression corre-
lates with poor outcome in patients with this disease [21]. miR-23b
has been reported to function as a renal cancer oncogene [22]. In
contrast, miR-23b is signiﬁcantly down-regulated in bladder can-
cer tissues and cell lines and that high expression level of miR-
23b positively correlate with higher overall survival of patients
after surgery, suggesting that it is a potential biomarker and tumor
suppressor in bladder cancer [23]. miR-23b is a methylation
silenced tumor suppressor in prostate cancer [24]. The overexpres-
sion of miR-23b leads to decreased migration and proliferation
abilities of hepatocellular carcinoma cells [25]. In the present
study, our data showed that miR-23b was functionally involved
in suppressing EOC cell growth, migration and invasion, which
was supported by both cell culture studies and clinical data. In cell
culture experiments, over-expression of miR-23b led to the de-
crease of EOC cell proliferation and cell motility. More importantly,
we conﬁrmed that miR-23b may function as a tumor suppressor
for EOC by targeting RUNX2. In clinical samples, miR-23b was dra-
matically down-regulated in EOC tissues with high clinical stage
compared with EOC tissues with low clinical stage, and low miR-
23b expression in tumors was associated with poor survival of pa-
tients with EOC. Notably, we have two different ﬁndings from the
previous studies. Firstly, postoperative residual tumor size has
been demonstrated to be an independent prognostic factor of PFS
and OS in EOC [26–28]. However, the current data did not shown
its prognostic value for patients with EOCs. Secondly, the OS in
EOC is generally very poor. According to the previous study, the
estimated 5-year OS of patients with EOCs is about 35% in stage
III–IV tumors [29,30]. However, our data in Fig. 5 showed a 5-year
OS of about 40% in the low miR-23b arm and approximately 70% in
the high miR-23b arm. These differences may be caused by the het-
erogeneity of our cohort and the relative small sample size in the
current study. To solve this problem, a randomized study investi-
gating the association between miR-23b expression and prognosis
should be conducted to conﬁrm whether miR-23b could be used as
a novel predictor of prognosis in patients with EOCs.
In conclusion, our data offer the convincing evidence for the
ﬁrst time that miR-23b may suppress tumor progression of EOC
through down-regulating RUNX2 and may be a potential prognos-
tic marker for this disease. Gene therapy using miR-23b mimics
may be useful for the treatment of EOC.
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